drugset / Trial / NCT01395394

Phenylketonuria, Oxidative Stress, and BH4

NCT01395394

Phase 2 Terminated 12 enrolled Emory University
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to see how tetrahydrobiopterin therapy (BH4; also known as sapropterin dihydrochloride or Kuvan) affects measures of oxidative stress and endothelial function in patients with Phenylketonuria (PKU).

Timeline

Start
2011-06
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject sapropterin Unknown 20 mg/kg

Indications